Farmas USA

ARNA

De ahora mismo

CAMELLIA-TIMI 61 study has reached its target enrollment of 12,000 patients at more than 470 sites in eight countries. The CAMELLIA-TIMI 61 outcomes study is designed to evaluate the impact of long-term treatment with BELVIQ® (lorcaserin HCl) CIV on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes mellitus in obese and overweight patients with cardiovascular disease and/or multiple cardiovascular risk factors.

http://www.streetinsider.com/Corporate+News/Eisai+and+Arena+%28ARNA%29+Complete+Enrollment+in+BELVIQ+CAMELLIA-TIMI+61+Study/11115312.html?si_client=intbro

CLSN

Sin novedad

Por ejemplo HZNP :-)

CYTX

Signing of a non-exclusive, 3 year distribution agreement with Worthington Biochemical Corporation for Celase® GMP enzyme for research markets in the U.S. and select international countries.

Celase® GMP is a proprietary enzyme containing a unique blend of collagenase, neutral protease and buffer salts that are produced using avian and mammalian tissue-free raw materials, aseptically processed, sterile filtered and highly purified under cGMP guidelines. Integrating Celase® GMP into cell isolation study protocols can facilitate a smooth transition from bench and animal research to downstream clinical applications.

http://finance.yahoo.com/news/cytori-worthington-enter-celase-gmp-130000846.html

Bueno , lo mismo las caídas son por miedo... como el que tenemos, y guarde quizás un cohete en sus entrañas,

Parece que le va sentando bien esta noticia de la conferencia de hoy, y si partía 1.36 era tendencia... veramos a ver, ayer cerró en 1.33 y está en pre market...

XOMA
Pre-market: 1.63 +0.30 (22.56%)

XOMA Corp (NASDAQ:XOMA) plunged -2.21% to finish last trading session at $1.33. The company, on Nov. 5, 2015, declared it has agreed to sell its biologics manufacturing facilities, equipment, and associated real estate to Agenus Inc. (AGEN). The transaction is expected to close in December 2015. In conjunction with the transaction, Agenus will offer employment to a select team of XOMA employees currently operating the facilities and may provide small-scale manufacturing services for XOMA in the future.

http://investorwired.com/biotech-stocks-is-it-still-worthwhile-trading-vertex-pharmaceuticals-incorporated-vrtx-xoma-corp-xoma-alexion-pharmaceuticals-inc-alxn/1776513

Triskis, no quito ojo a HZNP, quiero que me de regalo para navidad ... pero no encuentro el punto de entrada, quizas por los 20,6???

Eso si, tiene la MM20 y la M50 cruzandose pa'rriba ...

Como lo ves?

Lo sensato seria esperar a ver si supera esa alcista perdida , por encima de los 22 ... pero como nos gusta comprar barato pues ...

NVAX, GERN, EXEL, MNKD

Dicen que esperan muchas compras hoy por el rebalanceo de fondos

http://247wallst.com/healthcare-business/2015/12/01/huge-powershares-etf-rebalance-means-massive-buying-for-4-biotech-stocks/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+typepad%2FRyNm+%2824%2F7+Wall+St.%29

anda, ya tenemos entonces la explicacion a tanta subida de ayer, no? Ahi esta :)